自从采用嵌合抗原受体T细胞治疗（CAR-T治疗）极大地改变了B细胞肿瘤的治疗策略以来，各种CAR-T细胞产品已经被开发并应用于髓系和实体瘤的治疗。虽然病毒载体广泛用于产生基因工程T细胞，但基因工程的进展导致了非病毒、基因改良的CAR-T细胞的产生方法。最近的进展揭示了非病毒CAR-T细胞不仅对生产过程的简便性和非病毒载体的可获取性，而且对细胞本身的功能也具有显著的影响。在本综述中，我们重点介绍非病毒、基因改良的CAR-T细胞中基于piggyBac转座子的CAR-T细胞，并讨论它们的特性、临床前开发和最近的临床应用。 © 2023。作者独家授权给日本临床肿瘤学会。

Since the introduction of the use of chimeric antigen receptor T-cell therapy (CAR-T therapy) dramatically changed the therapeutic strategy for B cell tumors, various CAR-T cell products have been developed and applied to myeloid and solid tumors. Although viral vectors have been widely used to produce genetically engineered T cells, advances in genetic engineering have led to the development of methods for producing non-viral, gene-modified CAR-T cells. Recent progress has revealed that non-viral CAR-T cells have a significant impact not only on the simplicity of the production process and the accessibility of non-viral vectors but also on the function of the cells themselves. In this review, we focus on piggyBac-transposon-based CAR-T cells among non-viral, gene-modified CAR-T cells and discuss their characteristics, preclinical development, and recent clinical applications.© 2023. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.